Life Scientist > Biotechnology

CEO focus groups gather leaders' views

10 April, 2014

Biotech and medtech leaders are participating this week and next in focus groups to share their views and perspectives on industry policy and bolster the 2014 Biotechnology Industry Position Survey, due for release in May.


Avita Medical improves ReCell Spray-on Skin

09 April, 2014 by Dylan Bushell-Embling

Avita Medical (ASX:AVH) announced the EU launch of a version of its ReCell Spray-on Skin that eliminates the requirement for refrigeration, but the new version is not yet approved in Australia.


'Soft Landing' program to support access to Hong Kong and China

08 April, 2014

Hong Kong's 'Soft-landing Programme for Technology and Innovation Collaboration' is open to technology transfer offices (TTOs), research and development centres, research institutes and spin-out companies of overseas universities interested in exploring the Asian market, especially mainland China.


GI Dynamics scores Israeli win for EndoBarrier

08 April, 2014 by Dylan Bushell-Embling

GI Dynamics (ASX:GID) has revealed that its EndoBarrier therapy now has reimbursement coverage at one of Israel's four HMOs, and is now on offer at two more Australian clinics.


Reva fixed in focus on Fantom

07 April, 2014

Reva sticks to expediting its biodegradable stent Fantom to the clinic.


Global Kinetics to present at philanthropic forum

07 April, 2014 by Dylan Bushell-Embling

Melbourne's Global Kinetics will present details of the company and its Parkinson's Kinetograph symptom-monitoring device at a global philanthropic forum in New York in May.  


A new funding program to support biopharmaceutical manufacturing development

03 April, 2014

The first round of a new pilot funding program opens this week in Queensland, with at least $2 million available for biopharmaceutical product developers wanting to make use of BioPharmaceuticals Australia's (BPA) new mammalian cell contract manufacturing facility, operated by DSM Biologics (DSMB).


dorsaVi teams with insurer to promote OHS device

01 April, 2014 by Dylan Bushell-Embling

dorasVi (ASX:DVL) has entered a partnership with insurer Allianz to recommend the use of ViSafe - a device for measuring movement and muscle activity - for Australian labourers.


Simon McKeon to give National Press Club Address

01 April, 2014

AusBiotech has welcomed news that Simon McKeon AO will speak at the National Press Club in Canberra about the Strategic Review of Health and Medical Research in Australia.


Analytica close to US, EU filings for PeriCoach

01 April, 2014 by Dylan Bushell-Embling

Analytica (ASX:ALT) will soon be ready to file EU CE Mark and US 510(k) submissions for PeriCoach, a device for treating female urinary incontinence that is already approved in Australia.


pSivida partner files fourth US NDA for Iluvien

31 March, 2014 by Dylan Bushell-Embling

pSivida (ASX:PVA) licensee Alimera Sciences has made its third resubmission of its US New Drug Application for diabetic macular edema treatment Iluvien.


GI Dynamics hits Netherlands reimbursement milestone

28 March, 2014 by Dylan Bushell-Embling

A Dutch hospital has won approval to be reimbursed for some procedures involving GI Dynamics' (ASX:GID) EndoBarrier so that healthcare authorities can evaluate allowing nationwide reimbursement.


Government releases statement on the Pharmaceutical Patents Review

27 March, 2014

The federal government last week released a statement on the Pharmaceutical Patents Review report, confirming it "has no plans to respond to the report at this stage".


Cochlear's first-of-its-kind hybrid device gets regulatory approval in US

25 March, 2014

After the US FDA approved the first-of-its-kind hearing device, Cochlear has launched a new hybrid hearing solution that helps people's hearing by amplifying low-frequency hearing and restoring access to high-frequency hearing, and will open up new opportunities in the US market.


Cochlear cleared to sell new device in US

21 March, 2014 by Dylan Bushell-Embling

The FDA has granted Cochlear (ASX:COH) approval to sell the Nucleus Hybrid L24 - a new cochlear implant system designed to address high-frequency hearing loss - in the US.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd